Celadon Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 4/6
Celadon Pharmaceuticals has a total shareholder equity of £3.0M and total debt of £29.0K, which brings its debt-to-equity ratio to 1%. Its total assets and total liabilities are £9.5M and £6.4M respectively.
Key information
1.0%
Debt to equity ratio
UK£29.00k
Debt
Interest coverage ratio | n/a |
Cash | UK£1.61m |
Equity | UK£3.03m |
Total liabilities | UK£6.43m |
Total assets | UK£9.46m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: CEL's short term assets (£2.6M) exceed its short term liabilities (£1.4M).
Long Term Liabilities: CEL's short term assets (£2.6M) do not cover its long term liabilities (£5.0M).
Debt to Equity History and Analysis
Debt Level: CEL has more cash than its total debt.
Reducing Debt: Insufficient data to determine if CEL's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CEL has sufficient cash runway for 3 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: CEL is forecast to have sufficient cash runway for 2 months based on free cash flow estimates, but has since raised additional capital.